These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37828396)

  • 1. Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa.
    Aktas Z; Sonmez N; Oksuz L; Boral O; Issever H; Oncul O
    Braz J Microbiol; 2023 Dec; 54(4):2817-2826. PubMed ID: 37828396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
    Law JP; Wood AJ; Friman VP
    Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
    Attwood M; Griffin P; Noel AR; Albur M; Macgowan AP
    J Antimicrob Chemother; 2023 Sep; 78(9):2254-2262. PubMed ID: 37527369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
    MacLeod DL; Barker LM; Sutherland JL; Moss SC; Gurgel JL; Kenney TF; Burns JL; Baker WR
    J Antimicrob Chemother; 2009 Oct; 64(4):829-36. PubMed ID: 19679597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
    Anderson GG; Kenney TF; Macleod DL; Henig NR; O'Toole GA
    Pathog Dis; 2013 Feb; 67(1):39-45. PubMed ID: 23620118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.
    Schülin T
    J Antimicrob Chemother; 2002 Feb; 49(2):403-6. PubMed ID: 11815589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
    Buyck JM; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
    McCaughey G; Gilpin DF; Schneiders T; Hoffman LR; McKevitt M; Elborn JS; Tunney MM
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa.
    Takahashi K; Kanno H
    Antimicrob Agents Chemother; 1984 Nov; 26(5):789-91. PubMed ID: 6440482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
    Rodríguez-Rojas A; Maciá MD; Couce A; Gómez C; Castañeda-García A; Oliver A; Blázquez J
    PLoS One; 2010 Apr; 5(4):e10193. PubMed ID: 20419114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of mesenchymal stem cell treatment and colistin-fosfomycin combination on colistin-resistant Acinetobacter baumannii sepsis model.
    İzci F; Ture Z; Dinc G; Yay AH; Eren EE; Bolat D; Gönen ZB; Ünüvar GK; Yıldız O; Aygen B
    Eur J Clin Microbiol Infect Dis; 2023 Nov; 42(11):1365-1372. PubMed ID: 37814067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
    McCaughey G; Diamond P; Elborn JS; McKevitt M; Tunney MM
    PLoS One; 2013; 8(7):e69763. PubMed ID: 23936095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental Pseudomonas aeruginosa sepsis: absence of synergy between ticarcillin and tobramycin.
    Chusid MJ; Davis SD; Sarff LD
    J Lab Clin Med; 1983 Mar; 101(3):441-9. PubMed ID: 6402553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.